Introduction
The prevalence of antiphospholipid antibodies (aPL) in the general population is difficult to estimate due to the lack of population-based studies. The most frequently detectable aPL are anticardiolipin antibodies (aCL), antiβ2-glycoprotein I antibodies (anti-β2-GPI), and lupus anticoagulant (LAC). 1 A large review of the literature in 2013 estimated that the prevalence of aPL positivity is 6% among women with pregnancy complications, 10% among patients with deep venous thrombosis (DVT), 11% among patients with myocardial infarction, and 17% among patients with juvenile stroke (<50 years of age). As acknowledged by the Authors, this prevalence should be considered with caution, because 60% of the papers were published before 2000, all three criteria aPL tests were performed in only 11% of the papers, and 36% of papers used a low-titer aCL cut off. 2 Subjects carrying aPL who develop thrombotic complications are diagnosed with the antiphospholipid syndrome (APS), which was first described in 1983 by Hughes, who initially defined it as "anticardiolipin syndrome". 3 This definition was derived from clinical observation of recurrent miscarriages, central nervous system Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management Antiphospholipid syndrome
Diagnosis of antiphospholipid syndrome
Antiphospholipid syndrome is a systemic autoimmune disorder characterized by arterial and venous thrombotic manifestations and/or pregnancy morbidity in patients with persistently high levels of aPL. 6 APS may be classified as primary or secondary, the latter being present in 30-40% of patients with SLE. 7 The 2006 Sapporo criteria are those currently recommended to diagnose APS. 8 They include the presence of one clinical criterion and high values of at least one aPL among IgM/IgG aCL in serum or plasma, IgM/IgG anti-β2 glycoprotein-I (aβ2GPI) antibodies in serum or plasma, and LAC in plasma. Clinical and laboratory criteria are listed in Figure 1 . 7 The persistence of high antibody values should be tested at least 12 weeks apart, and, in addition, the antibody titers should be dosed at least 12 weeks after the thrombotic event but no more than five years afterwards. 7, 8 Of note, not all patients remain positive over time, and factors associated with persistence of aPL positivity are not well known, but may include inflammation and oxidative stress. 9 Subjects positive for aPL have a low risk of developing thrombotic events (<1%/year), but after a first episode, the risk of recurrence increases by 10-67%. 10 This finding was supported by a recent study performed by Kearon et al., 11 in which 307 patients with a first unprovoked VTE were tested for aPL. In this study, the persistence of aPL on ≥2 occasions was associated with an increased risk of recurrent thrombosis, despite negative D-Dimer values (HR 4.5: 95%CI: 1.5-13.0; P=0.006). 11
Clinical presentation of antiphospholipid syndrome
Antiphospholipid syndrome can be broadly classified in venous, arterial or obstetric APS, which are, however, not mutually exclusive. In a retrospective analysis of a cohort of 160 patients with a definite APS, VTE was the most common manifestation (47.5%), followed by arterial thromboembolism (43.1%), while obstetrical complications was found in only 9.7% of patients; in this study, catastrophic APS (C-APS) represented 2.5% of the cases. 12 Stroke and transient ischemic attack often involve APS patients, but also lower limb ischemia and myocardial infarction can occur. 12 In this context, the relationship between aPL and myocardial infarction seems to be bidi-Seronegative antiphospholipid syndrome haematologica | 2020; 105(3) rectional. Therefore, patients carrying aPL have an increased risk of ischemic heart disease, and conversely, after a first coronary artery disease event, patients positive for aPL showed twice the risk of recurrent major adverse cardiovascular events at 12 and 24 months. 13 This risk was also evident in subjects with juvenile myocardial infarction in absence of cardiovascular risk factors. 13 Concerning obstetric complications, fetal loss, especially after 10 th week of gestation and premature birth due to eclampsia or placental insufficiency are frequent complications in APS women. 14 In young women with a history of multiple miscarriage, the immunological study for aPL should be considered.
Finally, catastrophic APS (C-APS) is a severe and lifethreatening manifestation characterized by simultaneous venous or/and arterial thrombosis, often triggered by infections and surgical procedures. C-APS involves multiple organs and systems due to excess of proinflammatory cytokines, coagulation cascade, and platelet activation, leading to thrombosis and microangiopathic hemolytic anemia. 15 In addition to the above described signs and symptoms, the clinical presentation of patients with APS may be more heterogeneous, involving thrombosis of medium and small vessels (Table 1) . 6, 7, [16] [17] [18] The relevance in clinical practice of non-conventional APS criteria was investigated during the 14 th Congress on Antiphospholipid Antibodies, in which each relevant clinical manifestation was analyzed and each evidence was evaluated by the GRADE system. This system also considers the balance of patientimportant outcomes, the overall quality of the evidence for each outcome, and any uncertainty about values. 18 The most commonly affected sites are the kidney, the skin, and the cardiovascular and nervous systems. In the kidney, it is possible to find an acute thrombotic microangiopathy or a chronic pattern of vaso-occlusive lesions such as cortical ischemic lesions, arterial fibrous intimal hyperplasia or interstitial fibrosis. 6 APS nephropathy can be identified with a urine test associated with a 24-hour investigation of proteinuria. A biopsy is mandatory in cases where the cause is not clearly identifiable, as in patients with concomitant diabetes, uncontrolled arterial hypertension or other autoimmune diseases such as SLE.
Concerning the skin, livedo reticularis can be found, and recurrent ulcerations called livedoid vasculopathy have also been described. 8 To evaluate skin abnormalities, a clinical examination is often adequate, and there is usually no need for skin biopsy.
Cardiac abnormalities include valve leaflet thickening, 6 and diastolic dysfunction, especially of the right ventricle. 19 Heart valve disease and diastolic dysfunction can be investigated by resting transthoracic echocardiography and by cardiac magnetic resonance imaging (MRI) if a myocardial involvement is suspected (i.e. myocarditis). Pericardium may also be involved, especially in patients with APS and SLE.
Finally, APS is associated with an increased risk of dementia, seizures, multiple sclerosis-like illness, migraine, myelitis transversa and chorea, due to vascular damage and a direct action of antibodies on neurons and ependymal cells. 7, 20, 21 However, unlike other neurological disorders, seizure is not considered a non-conventional criterion due to lack of strength of evidence. 18 To identify critical illness such as neurological disorders, instrumental examinations are mandatory. An MRI and an electroencephalogram could be useful in recognizing brain atrophy associated with dementia and seizures, and could identify more elusive symptoms such as chorea and migraine if associated with an accurate physical examination.
Other blood alterations include thrombocytopenia (commonly mild with platelet count between 50x10 9 /L and 150x10 9 /L, but also severe with platelet counts <20x10 9 /L often associated with microangiopathy) and hemolytic anemia with the possible presence of schistocytes. 6 In particular, thrombocytopenia is common in APS, affecting 20-46% of patients and could paradoxically be associated with an increased risk of thrombosis. 18 Thrombocytopenia may be the result of an increased activation and destruction of platelets by an immune-mediated mechanism involving aPL or by thrombotic microangiopathy. 22 After the exclusion of a pseudo-thrombocytopenia, and performing a Coombs test to ascertain the autoimmune nature of thrombocytopenia, corticosteroids, immunosuppressive agents, immunoglobulins and new drugs such as Mammalian target of rapamycin (mTOR) inhibitors and monoclonal antibodies could be helpful in patients with autoimmune thrombocytopenia. 23
Definition of seronegative antiphospholipid syndrome and non-criteria antiphospholipid antibodies
The first definition of SN-APS was given in 2003 by Hughes and Khamashta 5 who described patients with clinical manifestations highly suggestive of APS in absence of the laboratory criteria such as LAC, aCL and aβ2GPI antibodies.
Seronegative APS is usually a diagnosis of exclusion and should be suspected in patients with a clinical history suggestive of APS, such as those with recurrent arterial venous thrombotic events, recurrent miscarriage, or unexplained thrombocytopenia, with persistent negativity of aPL tested on at least two occasions, and when other causes of throm- To better characterize the entity of SN-APS, antibodies against different phospholipids or protein co-factors have been investigated in patients negative to conventional aPL ( Table 2) .
The antibodies that have been most studied so far are those directed against: 1) a zwitterionic phospholipid, namely phosphatidylethanolamine (PE); 2) negatively charged phospholipids other than cardiolipin, including phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylinositol (PI); 3) vimentin (forming a complex with Seronegative antiphospholipid syndrome haematologica | 2020; 105(3) 565 Table 2 . Summary of positivity for extra-criteria antibodies in each study of seronegative antiphospholipid syndrome (SN-APS).
Authors

Study typology Population aPL positivity in SN-APS (n) Main findings (year)
P=prospective; studied R=retrospective CS=cross-sectional APS SN-APS IgA aPL aPE NCP AVA/CL aPS/PT aANX CaS= case series (n) (n)
negative for the APS laboratory criteria Kumar 83 CaS 47 CS 40 Table 2 ). In addition, the IgA isotype aβ2GPI is under investigation in APS and SN-APS patients.
A collaborative USA/UK study analyzed a comprehensive panel of 'non-criteria' aPL tests in a series of 175 consecutive patients matching the criteria for APS and 68 SN-APS patients with clinical manifestations suggestive of APS but having negative serology. The Authors found that one-third of the 'seronegative' sera gave positive results. 24 The study concluded that patients with clinical features of APS, but negative for conventional criteria markers, should undergo additional testing for non-criteria biomarkers. 24 A recent study evidenced that positivity for the extracriteria aPL was <1% in SN-APS (thrombotic or obstetric); however, the lack of clear inclusion and exclusion criteria does not allow a precise estimation of the prevalence to be made. 25 Similarly, non-criteria antibodies were detected in 18.8% of SN-APS patients also in a Chinese cohort composed of APS and patients with only clinical criteria for APS. 26 This is also confirmed in obstetric SN-APS patients, in whom 68% were positive for non-conventional aPL. 27 Here we will provide an overview of current evidence on the most studied non-criteria aPL that, although not validated in large cohort studies, may have a potential role in the pathogenesis of APS.
IgA antibody isotype anti-β 2 glycoprotein-I and anticardiolipin antibodies
There is a growing body of evidence to suggest a potential usefulness of IgA in the context of APS. 28 Very recent evidence suggested that, while IgG/M isotypes recognize an epitope in domain 1, the epitopes recognized by IgA are the domains 3, 4 and 5. 29 However, as reported by the 13 th International Congress on Antiphospholipid Antibodies, testing for IgA-aβ2GPI should be considered only in patients negative for IgG and IgM isotypes with APS symptoms. 30 Studies investigating the prevalence of IgA aPL reported a variable prevalence ranging from 14% to 72% according to different reports; 28 however, these studies have a retrospective design, used different assays to measure IgA aPL, and used different cut-off values to define aPL positivity. 31, 32 A large study including 5,892 patients (803 with SLE and 5,089 from the Antiphospholipid Standardization Laboratory sent for evaluation for APS) found that IgA aβ2GPI isotype was positive in 255 (4.3%) patients, in 198 cases in association with other aPL, while only aPL was detectable in 57. 33 Isolated IgA aβ2GPI positivity was associated with an increased risk of arterial thrombosis (P<0.001), venous thrombosis (P=0.015), and all thrombosis (P<0.001). 33 A second study evaluated, in addition to IgM and IgG, the positivity and predictivity of IgA aCL and IgA aβ2GPI in 430 patients: 111 with APS, 119 with SLE, and 200 healthy controls. 34 Positivity for IgA aCL was 38%; IgA aβ2GPI was 46% in patients with APS. All three antibody isotypes (IgM, IgG and IgA) were significantly associated with a diagnosis of APS, with high specificity but not good sensitivity, based on receiver operating characteristic (ROC) analysis. Looking at likely hazard ratios, the IgA aβ2GPI (HR 33.9, 95%CI: 10.5-109.5) was similarly asso-ciated to APS as compared to IgG aβ2GPI (HR 33.4, 95%CI: 13.0-86.1), but showed a higher association compared to IgM aβ2GPI (HR 9.2, 95%CI: 4.6-18.4) and was associated with thrombotic but not obstetric complications in patients with APS. 34 Indeed, IgA aβ2GPI levels seem to be associated with thrombotic events in patients without other aPL. 33, 35 Thus, a case-control study including 244 asymptomatic patients screened for aPL and positive only for IgA aβ2GPI and 221 negative patients followed for five years showed that the presence of IgA aβ2GPI was associated with an increased risk for developing clinical thrombotic APS events (OR 5.15; P<0.001). 36 Although attractive, these data were not confirmed by another study evaluating the presence of IgA aβ2GPI antibodies in SN-APS. 25 Based on this evidence, it is not clear whether testing for IgA aCL and IgA aβ2GPI antibodies in addition to the routine tests may improve thrombotic risk stratification. Thus, the use of IgA antibodies to identify a SN-APS needs to be further investigated.
Antibodies to phosphatidylethanolamine
Phosphatidylethanolamine is mainly found in the inner leaflets of plasma membranes and contributes to 20-50% of total phospholipids. It works as an anticoagulant by enhancing activated protein C (APC) activity. Other investigators have demonstrated that PE inhibits coagulation activity interfering with the factor Xa-prothrombin system. 37 Several studies reported that antibodies against PE (aPE) are significantly associated with major clinical events such as fetal loss and/or thrombosis, and are mainly present in the absence of the laboratory criteria of APS. Bérard et al. showed that aPE were the only aPL found in 6 of 34 patients suffering from thrombotic events and with a negative screening for antibodies to anionic phospholipids, including LA. 38 A second study focused on patients with unexplained thrombosis and no criteria for APS. Thus, in 98 patients with unexplained thrombosis, 142 with thrombophilia, 67 with APS, 75 with hereditary hemostatic defects and 110 without thrombosis, the authors found that aPE prevalence was significantly higher both in patients with APS (43%; P<0.0001) and in those with unexplained thrombosis (18%; P=0.001) compared to patients without thrombosis. 39 Subsequently, in a large multicenter study including 317 patients with deep venous thrombosis and 52 with arterial events, aPE were found in 15% of the thrombotic patients, most of whom were only positive for aPL. 40 Some interesting data were also reported regarding the association between aPE and obstetric complications. Gris et al. measured various aPL in a large cohort of 518 women with unexplained or explained early fetal losses and a control group of healthy mothers. IgM-aPE were found to be independent risk factors for unexplained early fetal loss. 41 A retrospective study on 228 SN-APS demonstrated a positivity for aPE in 10% of the patients. 42 In contrast, a recent study on a Chinese population composed of APS and patients with only clinical criteria for APS failed to demonstrate any aPE positivity in SN-APS. 26 The above reported results suggest that aPE could be considered as markers of a variant of APS when they are associated with thrombosis and a potential tool to define the SN-APS subjects.
Antibodies against phosphatidic acid, phosphatidylserine and phosphatidylinositol
In an effort to expand the panel of aPL to other negatively-charged phospholipids, antibodies against phosphatidic acid (PA), phosphatidylserine (PS), and phosphatidylinositol (PI), which fall under the category of anionic phospholipids, were proposed. 43 Anti-PS antibodies inhibited the development and invasion of the trophoblast, decreased hCG levels, and retarded the formation of syncytiotrophoblast in in vitro models. 44 Few clinical studies have investigated this issue. In a first study on 866 women with recurrent pregnancy loss (RPL), the authors found that 87 of 866 women who were negative for aCL had a positivity for one of the other aPL. 42 In a second study on 872 women with RPL, 49 (3.6%) were negative for both aCL and LA but positive for aPS. 46 In this second study, the presence of aPS had a positive correlation with the number of consecutive pregnancy losses. 46 This result was not confirmed when the same author analyzed a larger population of 1,020 woman with RPL. 46 Moreover, Zhang et al. did not find any positivity for aPE, aPS or aPI in an evaluation study of 288 subjects (86 patients with APS, 30 patients with non-APS thrombosis, 32 patients with non-APS pregnancy-related morbidity, 42 patients with SLE, and 39 healthy controls). 26 Based on the current evidence, testing for aPA, aPI and aPS is not recommended, as these antibodies appeared to overlap with the accepted diagnostic markers of APS. Nonetheless, the results obtained on RPL with a seronegative profile suggest a potential role for aPA, aPI and aPS in defining SN-APS in this particular setting.
Anti-vimentin/cardiolipin complex
Vimentin is the most abundant type III intermediate filament of the cytoskeletal system and it was recently localized on the surface of apoptotic neutrophils and T cells, activated macrophages, platelets, and vascular endothelial cells. After becoming antigenic with a still unexplained mechanism, Vimentin is exposed and could be bound by anti-vimentin antibodies (AVA). 47, 48 Vimentin could also electrically interact with cardiolipin on the surface of apoptotic cells generating the vimentin/cardiolipin complex. Antibodies against this complex (vimentin/cardiolipin antibodies, AVA/CL) show a prothrombotic effect. Thus, Ortona et al. demonstrated an AVA/CL-mediated activation of the TLR4/IRAK/Nf-kB molecular pathway that leads to the release of pro-inflammatory and procoagulant factors by endothelial cells. 47 Hence, AVA/CL could play a role in arterial thrombosis by inducing platelet and coagulation cascade activation.
The role of AVA/CL in SN-APS has been investigated only in a few clinical studies. Thus, Ortona et al. 47 analyzed serum IgG AVA/CL antibodies detected by ELISA in 29 SN-APS, 40 APS, 30 patients with SLE, 30 with rheumatoid arthritis, and 32 healthy controls. They found a positivity for AVA/CL in almost all APS patients (92%), and also in a large proportion of SN-APS (55%); interestingly, this positivity was persistent in almost all cases. Similarly, Conti et al. found AVA/CL positivity in 24 SN-APS patients. 49 Moreover, in a retrospective analysis of 61 obstetric SN-APS, 76% resulted positive for AVA/CL. 50 However, the overlapping presence of AVA/CL antibodies in SLE and APS weakens the specificity of such a diagnos-tic marker. Hence, the observation by Ortona et al. 47 needs to be confirmed by larger prospective clinical studies in order to better define the role of AVA/CL in SN-APS.
Anti-prothrombin and antiphosphatidylserine/prothrombin antibodies
Prothrombin is a plasma glycoprotein involved in the coagulation cascade converted to thrombin by extrinsic thromboplastin during the second stage of blood clotting. 51 A large amount of data, obtained from various, mainly retrospective, studies gave contrasting evidence concerning the clinical significance of anti-prothrombin antibody (aPT). Thus, in a comparison between 106 subjects who experienced either a non-fatal myocardial infarction or cardiac death and 106 subjects without coronary disease, Vaarala et al. found that a high level of aPT (highest tertile of distribution) predicted a 2.5-fold increase in the risk of cardiovascular events. 52 Conversely, Atsumi et al. did not find any correlation between clinical manifestation of aPT and APS in an evaluation of 265 APS patients. 53 More recently, two prospective studies validated the role of aPT in predicting the first or recurrent risk of thrombosis in patients with APS. 54, 55 Considering a group of 142 LA positive patients, Forastiero et al. found that a higher rate of thrombosis in patients with positive anti-PT compared with patients without anti-PT (8.6% vs. 3.5% per patient year). The highest incidence of thrombosis was detected in patients positive for both aβ2GPI and aPT (8.4% per patient year). 54 Moreover, a 15-year longitudinal prospective study by Bizzaro et al. identified IgG aPT antibody as the most useful thrombosis predictor in SLE patients. 55 Another intriguing issue is represented by the different potential role of IgG/IgM antiphosphatidylserine/prothrombin (aPS/PT) compared to aPT. Indeed, a high correlation between APS classical antibody panel and aPS/PT IgG/IgM suggests that this marker may be useful in the evaluation of APS. 56 The clinical significance of aPT and aPS-PT was evaluated by testing for the presence of these antibodies in 212 SLE patients and in 100 healthy individuals. Results show that aPT and aPS-PT were found in 47% of the patients (aPT in 31% and aPS-PT in 31%). Their presence did not correlate with that of aCL, aβ2GPI, LA and/or anti-protein S. IgG but not IgM aPT were more frequently found in patients with thrombosis than in those without. IgG and IgM aPS-PT were also more frequent in patients with thrombosis (venous and/or arterial) than in those without. Levels of IgG aPT and IgG and IgM aPS-PT were higher in patients with thrombosis than in those without. More significantly, 48% of the patients with aPL-related clinical features who were negative for standard tests had aPT. 57 Recently, the clinical significance of aPS/PT antibodies was prospectively evaluated in a cohort of 191 aPL carriers: 58 IgG aPS/PT antibodies were detected in 40 (20.9%) and IgM aPS/PT in 102 (53.4%) of the carriers. The cumulative incidence rate of thrombotic events was significantly higher in the IgG aPS/PT positive (P=0.035) but not in the IgM aPS/PT positive carriers. Similar results were obtained in a second study evaluating 152 patients with a previous thrombosis of whom 90 were SN-APS; 10% of SN-APS patients in this study were positive for aPS/PT. 59 Of note, aPS/PT are associated with recurrent early or late abortions and with premature delivery irrespective of other aPL. 60 Based on the above studies, aPT and aPS/PT can be potentially used as confirmatory diagnostic markers and as indicators of the risk of thrombosis. Recently, the presence of IgG and IgM aPS/PT was also detected in 9 of 17 SN-APS. 25 Similar, and even stronger evidence was provided by two retrospective studies on SN-APS patients that found approximately 50% of subjects were positive for aPS/PT. 61, 62 Nonetheless, further studies must be undertaken before these antibodies can be included in the diagnostic criteria of SN-APS.
Annexin A5 antibody
Annexin A5 is a glycoprotein that binds to negative phospholipids such as PS. It has been proposed that annexin A5 forms a protective anticoagulant shield on vascular endothelial cells and that aβ2GPI antibodies in complex with ß2GPI may disturb the shield and hence predispose to thrombosis. Due to this marked heterogeneity, it remains controversial whether anti-annexin A5 antibodies (aANX) are associated with clinical manifestations. In a comparison of 112 APS patients with 40 healthy controls, Singh et al. found aANX positivity in 69 APS and in only 3 controls. 63 On the contrary, de Laat et al. found no association between aANX and history of thrombosis in 198 patients with primary APS, SLE or lupus-like disease. 64 aANX was also found to be predictive for fetal loss in a study of three groups (total 518 women) of patients with unexplained primary recurrent early fetal loss, patients with explained episodes, and mothers with no previous obstetric incident, respectively. 41 Annexin A5 resistance was proposed as a mechanism for APS. The annexin A5 resistance (A5R) assay identifies patients with an antibody-mediated disruption of annexin A5 on endothelial surfaces. This is demonstrated by the resistance to the annexin A5 anticoagulant effects (i.e. annexin A5 resistance) in vitro. This test was validated in 750 patients with a history of thrombosis, pregnancy complications, and controls. 65 The authors found a reduction in A5 anticoagulant ratios in aPL antibody-positive patients with thrombosis and/or pregnancy complications compared with aPL antibody-negative patients and controls. This suggests that reduced A5R could identify patients with a propensity for thrombosis or pregnancy complications. 65 Very recently, a case report described the presence of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke, and SN-APS. 66 Hence, although attractive, the evaluation of aANX or A5R in clinical practice for the management of SN-APS requires larger prospective studies.
From risk assessment to antithrombotic treatment
The first step in the assessment of thrombotic risk in APS and SN-APS patients is represented by antibody characterization and evaluation of cardiovascular risk factors. Thus, the thrombotic risk varies according to aPL positivity and antibody titers. For example, a retrospective study on 3,088 APS patients demonstrated that single positivity for aCL or aβ2GPI was associated with low risk of event [odds ratio (OR) <5], while LA positivity alone conferred a medium risk of event (OR 5-9); this risk increased in patients with double or triple positivity (OR >9). 67 Some scores have also been proposed to stratify the risk of events in APS patients; the APL Score has no clinical items and is based exclusively on the antibody titers (Table 3) . 68 An aPL score of ≥30 was an independent risk factor for thrombosis (hazard ratio 3.144, 95%CI: 1.383-7.150; P=0.006) in patients with autoimmune diseases. 69 Another score is the Global Anti-Phospholipid Syndrome Score (GAPSS), which was developed in a cross-sectional study on a cohort of 211 patients with SLE. The score includes traditional cardiovascular risk factors such as hypertension and hyperlipidemia and the presence / absence of aPL70 (Table 3 ). Of note, both scores also include one non-criteria aPL, such as aPS/PT. These scores, although potentially useful in clinical practice, require further prognostic validation.
The thrombotic risk stratification is more challenging in patients with SN-APS. It is important to identify and characterize the presence of non-criteria aPL, as they seem to be associated with different thrombotic complications (Table 4 ). Thus, aPS/PT and antibodies to vimentin/CL complex increase the risk of arterial thrombosis, while pregnancy-related complications are associated with the presence of PE, PA, PS and PI antibodies ( 
Primary and secondary prevention strategies
Antiphospholipid antibody carriers
In subjects with positivity for aPL in the absence of clinical thrombotic events, primary prevention strategy includes cardiovascular risk factors such as arterial hypertension, diabetes, dyslipidemia and cigarette smoking ( Figure 2 ). Treatment with low-dose aspirin (LDA, 75-100 mg/die) is still controversial 6 and could be considered in patients at high risk, such as those with triple positivity or persistent positivity with medium-high titer of aCL. 71, 72 Recently, the positivity for IgG aPS/PT has been suggested as a marker of thrombotic risk in aPL carriers in addition to triple positivity ( Figure 2 ). 58 Regarding oral anticoagulation, with or without LDA, the quality of evidence is too low to demonstrate benefit or harm of anticoagulant use in aPL carriers. 73 In women with a high-risk aPL profile but no history of thrombosis or pregnancy complications, treatment with LDA (75-100 mg daily) during pregnancy should be considered according to 2019 European League Against Rheumatism (EULAR) recommendations.
Secondary antiphospholipid syndrome
In APS patients with previous arterial or venous thromboembolism, use of unfractionated or low molecular weight heparins (LMWH) is recommended in the acute phase 6 followed by long-term treatment with warfarin, with an international normalized ratio (INR) range between 2-3. 8, 74 Warfarin therapy in APS has several critical points. Indeed, a recent study 10 showed that, in the APS population, the management of anticoagulant therapy is more problematic compared to a population of patients with Table 4 . Suggested extra-criteria antibodies in seronegative antiphospholipid syndrome and its clinical manifestations. atrial fibrillation (AF). Thus, APS patients had a shorter time within the therapeutic range than those with AF (53.5% vs. 68%; P=0.001) and needed a higher mean weekly dose of warfarin to reach the therapeutic range. 10 In the case of low-quality therapy with warfarin or recurrent thrombosis, two possible therapeutic approaches could be considered. The first is to adopt a higher intensity warfarin therapy with target INR 3-4, which is, however, not current practice given its association with a reduced risk of thrombosis in the majority of patients. 6, 72, 75 A second approach is represented by the addition of LDA to anticoagulation, which should, however, be reserved for highrisk patients, particularly after an arterial thrombotic event. 6, 76 More recently, non-vitamin K antagonist oral anticoagulants (NOAC) have been investigated in patients with APS with divergent results. 77 Following the results from the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS), 78 which included triple positive thrombotic APS, rivaroxaban is contraindicated in APS patients with triple aPL positivity. 72 An analysis from the RE-COVER/RE-COVER II and RE-MEDY trials showed similar safety and efficacy of dabigatran in patients with thrombophilia and previous venous thromboembolic events, in whom APS represented the second most common inherited disorders, accounting for 20% of all patients. 79 These results need to be confirmed in realworld studies. A randomized trial investigating the efficacy and safety of apixaban in APS patients is currently ongoing; 80 this study will include patients with both venous and arterial thrombosis. Laboratory testing of NOAC may be useful in patients with APS as no pre-clinical data in this patient population are available.
Extra-critera antibodies Clinical manifestations
Recently, new drugs have been administered in APS patients with thrombotic events. A first example is represented by mTOR inhibitors; these were found to reduce the onset of new vascular lesions after transplantation in patients with APS nephropathy. 81 Monoclonal antibodies such as rituximab 82 (anti-CD20 agent) and eculizumab 23 (anti-C5 agent) are currently administrated to manage noncriteria symptoms refractory to standard therapy and to add-on in catastrophic APS and kidney transplantation in APS patients, respectively. Despite these findings, the use of these drugs should be avoided due to lack of strong evidence in APS patients; their use could be considered in patients with refractory C-APS, as suggested by EULAR guidelines. 72
Obstetric antiphospholipid syndrome
Women who are diagnosed with confirmed APS should be treated with antepartum administration of prophylactic or intermediate dose of unfractionated heparin or prophylactic LMWH combined with LDA (75-100 mg/day), according to the 2012 American College of Cardiology (ACC) guidelines. 74 Recent 2019 EULAR recommendations suggest that women: 1) with a history of obstetric APS, such as a history of ≥3 recurrent spontaneous miscarriages <10 th week of gestation and in those with a history of fetal loss (≥10 th week of gestation); and 2) with a history of delivery <34 weeks of gestation due to eclampsia/severe pre-eclampsia or due to placental insufficiency, should be started on a combined therapy including LDA and prophylactic heparin during pregnancy. 72 Heparin at prophylactic dose should be maintained for six weeks after delivery to avoid maternal thrombosis. Finally, heparin should be increased to therapeutic doses, in addition to LDA, in women with a history of thrombotic APS.
Conclusions
The diagnosis of SN-APS should be formulated only after the exclusion of other causes of inherited and acquired thrombophilic conditions. Although several different antibodies to a number of antigens are involved in SN-APS, the routine testing of these non-criteria antibodies is not recommended, but may be considered in patients with a high clinical suspicion of APS, such as those presenting with recurrent unexplained thrombosis, thrombosis at unusual sites, or women with recurrent pregnancy-related complications. The assessment and interpretation of these non-conventional antibodies should be performed by specialized centers of hemostasis and thrombosis to reduce laboratory variability.
The detection of non-criteria aPL may help guide antithrombotic strategies in SN-APS patients with arterial or venous thrombosis. As an example, patients treated with NOAC for recurrent VTE events, who become positive for non-criteria aPL, may be switched to VKA or LMWH, especially in cases of a recurrent thrombotic events. Moreover, in case of an unprovoked DVT, and among patients who could be withdrawn from anticoagulation, the positivity for a non-criteria aPL may help decide whether or not to continue long-term anticoagulation.
In conclusion, there is growing evidence to suggest a role for non-criteria aPL in those patients defined as "seronegative".
